Literature DB >> 16795005

2'-deoxy-4'-C-ethynyl-2-fluoroadenosine, a nucleoside reverse transcriptase inhibitor, is highly potent against all human immunodeficiency viruses type 1 and has low toxicity.

Hiroshi Ohrui1.   

Abstract

An idea to use 4'-C-substituted-2'-deoxynucleoside derivatives was proposed based on a working hypothesis to solve the problems of existing acquired immune deficiency syndrome chemotherapy (highly active antiretroviral therapy). Subsequent studies have successfully proved the validity of the idea and resulted in the development of 2'-deoxy-4'-C-ethynyl-2-fluoroadenosine, a nucleoside reverse transcriptase inhibitor, which is highly potent to all human immunodeficiency viruses type 1 (HIV-1s) including multidrug-resistant HIV-1 and has a low toxicity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16795005     DOI: 10.1002/tcr.20078

Source DB:  PubMed          Journal:  Chem Rec        ISSN: 1528-0691            Impact factor:   6.771


  15 in total

Review 1.  Emerging reverse transcriptase inhibitors for HIV-1 infection.

Authors:  Mohammad A Rai; Sam Pannek; Carl J Fichtenbaum
Journal:  Expert Opin Emerg Drugs       Date:  2018-05-10       Impact factor: 4.191

2.  EFdA, a reverse transcriptase inhibitor, potently blocks HIV-1 ex vivo infection of Langerhans cells within epithelium.

Authors:  Takamitsu Matsuzawa; Tatsuyoshi Kawamura; Youichi Ogawa; Kenji Maeda; Hirotomo Nakata; Kohji Moriishi; Yoshio Koyanagi; Hiroyuki Gatanaga; Shinji Shimada; Hiroaki Mitsuya
Journal:  J Invest Dermatol       Date:  2013-11-11       Impact factor: 8.551

3.  Structural basis of HIV inhibition by translocation-defective RT inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA).

Authors:  Zhe Li Salie; Karen A Kirby; Eleftherios Michailidis; Bruno Marchand; Kamalendra Singh; Lisa C Rohan; Eiichi N Kodama; Hiroaki Mitsuya; Michael A Parniak; Stefan G Sarafianos
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-03       Impact factor: 11.205

4.  4'-modified nucleoside analogs: potent inhibitors active against entecavir-resistant hepatitis B virus.

Authors:  Yuki Takamatsu; Yasuhito Tanaka; Satoru Kohgo; Shuko Murakami; Kamalendra Singh; Debananda Das; David J Venzon; Masayuki Amano; Nobuyo Higashi-Kuwata; Manabu Aoki; Nicole S Delino; Sanae Hayashi; Satoru Takahashi; Yoshikazu Sukenaga; Kazuhiro Haraguchi; Stefan G Sarafianos; Kenji Maeda; Hiroaki Mitsuya
Journal:  Hepatology       Date:  2015-08-25       Impact factor: 17.425

5.  MK-8591 (4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine) Exhibits Potent Activity against HIV-2 Isolates and Drug-Resistant HIV-2 Mutants in Culture.

Authors:  Vincent H Wu; Robert A Smith; Sara Masoum; Dana N Raugi; Selly Ba; Moussa Seydi; Jay A Grobler; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

Review 6.  Antimicrobial strategies: inhibition of viral polymerases by 3'-hydroxyl nucleosides.

Authors:  Jerome Deval
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 7.  4'-Ethynyl-2-fluoro-2'-deoxyadenosine, MK-8591: a novel HIV-1 reverse transcriptase translocation inhibitor.

Authors:  Martin Markowitz; Stefan G Sarafianos
Journal:  Curr Opin HIV AIDS       Date:  2018-07       Impact factor: 4.283

8.  4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms.

Authors:  Eleftherios Michailidis; Andrew D Huber; Emily M Ryan; Yee T Ong; Maxwell D Leslie; Kayla B Matzek; Kamalendra Singh; Bruno Marchand; Ariel N Hagedorn; Karen A Kirby; Lisa C Rohan; Eiichi N Kodama; Hiroaki Mitsuya; Michael A Parniak; Stefan G Sarafianos
Journal:  J Biol Chem       Date:  2014-06-26       Impact factor: 5.157

9.  Potent activity of a nucleoside reverse transcriptase inhibitor, 4'-ethynyl-2-fluoro-2'-deoxyadenosine, against human immunodeficiency virus type 1 infection in a model using human peripheral blood mononuclear cell-transplanted NOD/SCID Janus kinase 3 knockout mice.

Authors:  Shinichiro Hattori; Kazuhiko Ide; Hirotomo Nakata; Hideki Harada; Shinya Suzu; Noriyuki Ashida; Satoru Kohgo; Hiroyuki Hayakawa; Hiroaki Mitsuya; Seiji Okada
Journal:  Antimicrob Agents Chemother       Date:  2009-06-22       Impact factor: 5.191

10.  Development of modified nucleosides that have supremely high anti-HIV activity and low toxicity and prevent the emergence of resistant HIV mutants.

Authors:  Hiroshi Ohrui
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2011       Impact factor: 3.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.